Back to news

Biohaven jumps as investors react to cash-rich Ono licensing deal and platform validation

Investivoq PriceTracker

Biohaven Ltd. (BHVN) is up 30.4% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely catalyst is investor enthusiasm around Biohaven’s recently disclosed licensing agreement with Ono, which brings meaningful non-dilutive cash, royalties, and outside validation for its MoDE IgG degrader platform. The move also appears supported by renewed attention on lead candidate BHV-1300 in Phase 3 for Graves’ disease and broader pipeline momentum, including an upcoming oncology data presentation.

Details:

  • Biohaven announced a strategic regional licensing agreement with Ono covering BHV-1300, BHV-1310, and BHV-1320 in Japan, South Korea, Taiwan, and ASEAN markets.
  • The deal includes up to $100 million in near-term payments, with $80 million upfront, a possible additional $20 million milestone within a year, and royalties of about 20% on net sales in the licensed territory.
  • Biohaven retained rights outside the licensed region, including the United States, Europe, and China, which can be viewed positively because the company monetized part of the program without giving up its largest future markets.
  • BHV-1300 remains in Phase 3 development for Graves’ disease, and Biohaven also recently highlighted that BHV-1530 was selected for an oral presentation at a major cancer symposium, reinforcing broader interest in the pipeline.

    • Sources:

    Biohaven, SEC, StocksToTrade

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    Investivoq Alerts
    Receive BHVN Data Alerts
    Get market-moving data, filings, and signals for BHVN in real time.
    Sign Up

    $BHVN Hedge Fund Activity

    We have seen 147 institutional investors add shares of $BHVN stock to their portfolio, and 111 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    • WOODLINE PARTNERS LP added 7,359,891 shares (+2450.1%) to their portfolio in Q2 2026, for an estimated $109,515,178
    • TCG CROSSOVER MANAGEMENT, LLC removed 2,851,365 shares (-61.6%) from their portfolio in Q2 2026, for an estimated $42,428,311
    • AQR CAPITAL MANAGEMENT LLC added 2,175,100 shares (+110.1%) to their portfolio in Q2 2026, for an estimated $32,365,488
    • BLACKROCK, INC. added 1,988,178 shares (+17.7%) to their portfolio in Q2 2026, for an estimated $29,584,088
    • RUBRIC CAPITAL MANAGEMENT LP added 1,721,493 shares (+inf%) to their portfolio in Q2 2026, for an estimated $25,615,815
    • EXODUSPOINT CAPITAL MANAGEMENT, LP removed 1,501,099 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $22,336,353
    • D. E. SHAW & CO., INC. added 1,495,961 shares (+55.5%) to their portfolio in Q2 2026, for an estimated $22,259,899

    To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.

    $BHVN Price Targets

    Multiple analysts have issued price targets for $BHVN recently. We have seen 4 analysts offer price targets for $BHVN in the last 6 months, with a median target of $14.5.

    Here are some recent targets:

    • Jason Gerberry from B of A Securities set a target price of $11.0 on 06/29/2026
    • Douglas Tsao from HC Wainwright & Co. set a target price of $10.0 on 05/26/2026
    • Terence Flynn from Morgan Stanley set a target price of $18.0 on 05/13/2026
    • Leonid Timashev from RBC Capital set a target price of $22.0 on 05/05/2026

    This article is not financial advice. See Investivoq's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.